A business in context

ZBIO research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-10-22 · 8029 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 8-K · Current report

    Report date 2026-10-12 · 0001104659-26-115151 · Items 7.01,9.01

  2. 4 · Ownership change

    Report date 2026-09-01 · 0001104659-26-104728

  3. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001104659-26-095448

  4. 8-K · Current report

    Report date 2026-08-12 · 0001104659-26-095437 · Items 2.02,5.02,9.01

  5. 4 · Ownership change

    Report date 2026-06-15 · 0001193125-26-274473

  6. 4 · Ownership change

    Report date 2026-06-15 · 0001104659-26-075257

  7. 4 · Ownership change

    Report date 2026-06-15 · 0001104659-26-075256

  8. 4 · Ownership change

    Report date 2026-06-15 · 0001104659-26-075255

  9. 4 · Ownership change

    Report date 2026-06-15 · 0001104659-26-075254

  10. 4 · Ownership change

    Report date 2026-06-15 · 0001104659-26-075253

  11. 4 · Ownership change

    Report date 2026-06-15 · 0001104659-26-075252

  12. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001104659-26-059735

  13. 8-K · Current report

    Report date 2026-05-11 · 0001104659-26-059700 · Items 2.02,5.02,5.07,9.01

  14. 8-K · Current report

    Report date 2026-03-26 · 0001104659-26-037821 · Items 1.01,2.03,8.01,9.01

  15. DEF 14A · Proxy statement

    Report date 2026-05-11 · 0001104659-26-028062

  16. 10-K · Annual report

    Report date 2025-12-31 · 0001104659-26-027964

  17. 8-K · Current report

    Report date 2026-03-16 · 0001104659-26-027961 · Items 2.02,9.01

  18. 8-K · Current report

    Report date 2026-02-10 · 0001104659-26-015314 · Items 5.02,9.01

  19. 8-K · Current report

    Report date 2026-01-05 · 0001104659-26-000402 · Items 2.02,7.01,8.01,9.01

  20. 8-K · Current report

    Report date 2025-12-10 · 0001104659-25-121182 · Items 5.02,9.01

  21. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001104659-25-109753

  22. 8-K · Current report

    Report date 2025-11-12 · 0001104659-25-109737 · Items 2.02,9.01

  23. 8-K · Current report

    Report date 2025-10-27 · 0001104659-25-102317 · Items 7.01,8.01,9.01

  24. 8-K · Current report

    Report date 2025-10-07 · 0001104659-25-097663 · Items 1.01,2.02,3.02,7.01,8.01,9.01

  25. 8-K · Current report

    Report date 2025-09-02 · 0001104659-25-085982 · Items 1.01,2.01,2.03,7.01,9.01

  26. 10-Q · Quarterly report

    Report date 2025-06-30 · 0001558370-25-011147

  27. 8-K · Current report

    Report date 2025-08-12 · 0001104659-25-076464 · Items 2.02,9.01

  28. 8-K · Current report

    Report date 2025-06-10 · 0001104659-25-058892 · Items 5.02,5.07

  29. 8-K · Current report

    Report date 2025-06-04 · 0001104659-25-056215 · Items 7.01,9.01

  30. 10-Q · Quarterly report

    Report date 2025-03-31 · 0001558370-25-007803

  31. 8-K · Current report

    Report date 2025-05-15 · 0001104659-25-048948 · Items 2.02,9.01

  32. DEF 14A · Proxy statement

    Report date 2025-06-10 · 0001104659-25-039765

  33. 10-K · Annual report

    Report date 2024-12-31 · 0001558370-25-002631

  34. 8-K · Current report

    Report date 2025-02-05 · 0001104659-25-009368 · Items 2.02,9.01

  35. 8-K · Current report

    Report date 2024-12-02 · 0001104659-24-124616 · Items 7.01,9.01

  36. 10-Q · Quarterly report

    Report date 2024-09-30 · 0001558370-24-015162

  37. 8-K · Current report

    Report date 2024-11-12 · 0001104659-24-116346 · Items 2.02,9.01

  38. SC 13G · Ownership disclosure

    0000315066-24-002940

  39. SC 13G · Ownership disclosure

    0001326732-24-000055

  40. SC 13G · Ownership disclosure

    0001072613-24-000733

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-10-15 · 2026 Q3: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 0 transaction rows0SGrant / award: 1 transaction rows1AExercise / conversion: 0 transaction rows0MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

1 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-09-01
2026-09-02
Oliger Christy J.A · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
37000.00.0

Identity & relationships

Wikidata structured data · retrieved 2026-10-15 · 1663 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001953926Zenas BioPharma, Inc.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-10-15 · 1199 checked identities; 0 unavailable records

Search names and former names
  • Zenas BioPharma (Cayman) Ltd · former SEC name · 2022-11-15 to 2022-11-15

Revenue in constant purchasing power

USD revenue expressed in 2026-09 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

Year endedReported USD revenueCPI-adjusted USD revenue
2024-12-31$5.00M$5.37M
2023-12-31$50.00M$55.29M

Bureau of Labor Statistics · retrieved 2026-10-22 · 9 selected series; gaps remain missing

Explore the CPI history ↗